Dysport® is the first botulinum toxin to achieve positive topline Phase III results in both episodic and chronic migraine.

Dysport® achieved statistically significant topline Phase III results, meeting primary endpoints in both episodic (E-BEOND) and chronic (C-BEOND) migraine Dysport is the first botulinum toxin in episodic migraine to demonstrate a statistically significant reduction in monthly migraine days Dysport was well-tolerated across both trials with safety consistent with the known profile PARIS, FRANCE – 9 […]